Showing 1081-1090 of 1791 results for "".
- SEEN Hair Care Closes $9 Million in Series A Fundinghttps://practicaldermatology.com/news/seen-hair-care-closes-9-million-series-funding/2468305/SEEN, the award-winning haircare brand developed by dermatologist Iris Rubin, MD, has closed a $9 million Series A funding. The company said in a press release that this investment will “accelerate SEEN's growth as the premier science-backed, clinically-proven beauty brand, which sits at the inte
- Inaugural ElderDerm Conference Hosted by GWhttps://practicaldermatology.com/news/inaugural-elderderm-conference-hosted-gw/2467204/The inaugural ElderDerm Conference was held June 6 in Washington, DC, hosted by the GW Department of Dermatology. Co-Director Adam Friedman, MD, a Practical DermatologyÒ Editorial Board member, presented two talks: “Hair Loss in the Elderly: Considerations and Therapeutic Approaches” and
- Study: Potential for Combined Laser Treating Vascular and Pigmented Lesionshttps://practicaldermatology.com/news/combined-laser-shows-potential-vascular-and-pigmented-lesions/2462743/A novel laser with cryogen cooling long-pulsed options of both 532nm and 1,064nm laser offers laser surgeons a safe and effective way to treat vascular and pigmented lesions with a single device and significantly different clinical endpoints, wrote Nicole M. Golbari, MD, of the University of Cali
- Gene Variants May Drive Persistent Lesions in Darier Diseasehttps://practicaldermatology.com/news/gene-variants-may-drive-persistent-lesions-darier-disease/2462509/Persistent lesions in patients with Darier disease were associated with second-hit variants in the ATP2A2 gene, according to data from a new case series of 9 patients. In a study published in JAMA Dermatology, Lihi Atzmony, MD, of Rabin Medical Center, Petach Tikva, Israel, and c
- FDA Approves First Medication to Treat Severe Frostbitehttps://practicaldermatology.com/news/fda-approves-first-medication-to-treat-severe-frostbite/2462244/The FDA has approved Eicos Sciences' Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation. “This approval provides patients with the first-ever treatment option for severe frostbite,” Norman Stockbridge, MD, PhD
- Dr. Mario E. Lacouture Named New Chief of Dermatology at NYU Langone Hospital--Long Islandhttps://practicaldermatology.com/news/dr-mario-e-lacouture-named-new-chief-of-dermatology-at-nyu-langone-hospital-long-island/2462164/Mario E. Lacouture, MD, has been named the new Chief of the Dermatology Division, Department of Medicine of NYU Langone Hospital--Long Island. Dr. Lacouture will receive an academic appointment as Professor of Medicine at NYU Grossman School of Medicine, and will serve as the Medic
- Dr. Shawn Kwatra Named New Chair of Dermatology at the UM School of Medicine, Chief of Service of Dermatology at UM Medical Centerhttps://practicaldermatology.com/news/dr-shawn-kwatra-named-new-chair-of-dermatology-at-the-um-school-of-medicine-chief-of-service-of-dermatology-at-um-medical-center/2462002/Shawn Kwatra, MD will become the next Chair of the University of Maryland’s School of Medicine Department of Dermatology and Chief of Service of Dermatology at the University of Maryland Medical Center (UMMC), following a national search. Dr. Kwatra, who will begin
- New Surgical Technique Offers Hope to Folliculitis Decalvans Patientshttps://practicaldermatology.com/news/experimental-surgical-technique-offers-hope-to-folliculitis-decalvans-patients/2461997/The lack of long-term solutions in the challenging treatment of folliculitis decalvans (FD) led Sanusi Umar MD, and colleagues from Dr. U Hair and Skin Clinic to develop and patent a novel device that holds potential for sustained FD remission.
- ABMS Announces Class of 2023-2024 Visiting Scholarshttps://practicaldermatology.com/news/abms-announces-class-of-2023-2024-visiting-scholars/2461993/Gillian Heinecke, MD, an assistant clinical professor at SSM Health/Saint Louis University in St. Louis, Mo. is the American Board of Dermatology’s 2023-2024 Visiting Scholar. The American Board of Medical Specialties (ABMS) selected thirteen outstanding indivi
- Tarsus Rolls Out XDEMVY for Demodex Blepharitishttps://practicaldermatology.com/news/tarsus-rolls-out-xdemvy-for-demodex-blepharitis/2461985/Tarsus Pharmaceuticals, Inc. is rolling out XDEMVY, the First and Only US Food and Drug Administration-approved treatment for Demodex blepharitis. XDEMVY is now available at pharmacies nationwide for prescription. Bobak Azamian, MD, PhD, Chief Executive Officer, and Chairman, ran